Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.
Identifieur interne : 003385 ( PubMed/Corpus ); précédent : 003384; suivant : 003386Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.
Auteurs : Daniel J. Tisch ; Moses J. Bockarie ; Zachary Dimber ; Benson Kiniboro ; Nandao Tarongka ; Fred E. Hazlett ; Will Kastens ; Michael P. Alpers ; James W. KazuraSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2008.
English descriptors
- KwdEn :
- Animals, Antibodies, Helminth (blood), Antigens, Helminth (blood), Antiparasitic Agents (administration & dosage), Antiparasitic Agents (therapeutic use), Child, Child, Preschool, Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (immunology), Elephantiasis, Filarial (prevention & control), Follow-Up Studies, Humans, Infant, Ivermectin (administration & dosage), Ivermectin (therapeutic use), Papua New Guinea (epidemiology), Wuchereria bancrofti (immunology), Wuchereria bancrofti (isolation & purification).
- MESH :
- chemical , administration & dosage : Antiparasitic Agents, Ivermectin.
- chemical , blood : Antibodies, Helminth, Antigens, Helminth.
- chemical , therapeutic use : Antiparasitic Agents, Diethylcarbamazine, Ivermectin.
- geographic , epidemiology : Papua New Guinea.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- immunology : Elephantiasis, Filarial, Wuchereria bancrofti.
- isolation & purification : Wuchereria bancrofti.
- prevention & control : Elephantiasis, Filarial.
- Animals, Child, Child, Preschool, Drug Therapy, Combination, Follow-Up Studies, Humans, Infant.
Abstract
Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in Wuchereria bancrofti microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.
PubMed: 18256431
Links to Exploration step
pubmed:18256431Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.</title><author><name sortKey="Tisch, Daniel J" sort="Tisch, Daniel J" uniqKey="Tisch D" first="Daniel J" last="Tisch">Daniel J. Tisch</name><affiliation><nlm:affiliation>Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio 44106-7286, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name></author><author><name sortKey="Dimber, Zachary" sort="Dimber, Zachary" uniqKey="Dimber Z" first="Zachary" last="Dimber">Zachary Dimber</name></author><author><name sortKey="Kiniboro, Benson" sort="Kiniboro, Benson" uniqKey="Kiniboro B" first="Benson" last="Kiniboro">Benson Kiniboro</name></author><author><name sortKey="Tarongka, Nandao" sort="Tarongka, Nandao" uniqKey="Tarongka N" first="Nandao" last="Tarongka">Nandao Tarongka</name></author><author><name sortKey="Hazlett, Fred E" sort="Hazlett, Fred E" uniqKey="Hazlett F" first="Fred E" last="Hazlett">Fred E. Hazlett</name></author><author><name sortKey="Kastens, Will" sort="Kastens, Will" uniqKey="Kastens W" first="Will" last="Kastens">Will Kastens</name></author><author><name sortKey="Alpers, Michael P" sort="Alpers, Michael P" uniqKey="Alpers M" first="Michael P" last="Alpers">Michael P. Alpers</name></author><author><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W" last="Kazura">James W. Kazura</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18256431</idno><idno type="pmid">18256431</idno><idno type="wicri:Area/PubMed/Corpus">003385</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003385</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.</title><author><name sortKey="Tisch, Daniel J" sort="Tisch, Daniel J" uniqKey="Tisch D" first="Daniel J" last="Tisch">Daniel J. Tisch</name><affiliation><nlm:affiliation>Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio 44106-7286, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name></author><author><name sortKey="Dimber, Zachary" sort="Dimber, Zachary" uniqKey="Dimber Z" first="Zachary" last="Dimber">Zachary Dimber</name></author><author><name sortKey="Kiniboro, Benson" sort="Kiniboro, Benson" uniqKey="Kiniboro B" first="Benson" last="Kiniboro">Benson Kiniboro</name></author><author><name sortKey="Tarongka, Nandao" sort="Tarongka, Nandao" uniqKey="Tarongka N" first="Nandao" last="Tarongka">Nandao Tarongka</name></author><author><name sortKey="Hazlett, Fred E" sort="Hazlett, Fred E" uniqKey="Hazlett F" first="Fred E" last="Hazlett">Fred E. Hazlett</name></author><author><name sortKey="Kastens, Will" sort="Kastens, Will" uniqKey="Kastens W" first="Will" last="Kastens">Will Kastens</name></author><author><name sortKey="Alpers, Michael P" sort="Alpers, Michael P" uniqKey="Alpers M" first="Michael P" last="Alpers">Michael P. Alpers</name></author><author><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W" last="Kazura">James W. Kazura</name></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="ISSN">0002-9637</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Helminth (blood)</term><term>Antigens, Helminth (blood)</term><term>Antiparasitic Agents (administration & dosage)</term><term>Antiparasitic Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (immunology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Follow-Up Studies</term><term>Humans</term><term>Infant</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (therapeutic use)</term><term>Papua New Guinea (epidemiology)</term><term>Wuchereria bancrofti (immunology)</term><term>Wuchereria bancrofti (isolation & purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparasitic Agents</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term><term>Antigens, Helminth</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparasitic Agents</term><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Papua New Guinea</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Drug Therapy, Combination</term><term>Follow-Up Studies</term><term>Humans</term><term>Infant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in Wuchereria bancrofti microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18256431</PMID><DateCreated><Year>2008</Year><Month>02</Month><Day>07</Day></DateCreated><DateCompleted><Year>2008</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9637</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of tropical medicine and hygiene</Title><ISOAbbreviation>Am. J. Trop. Med. Hyg.</ISOAbbreviation></Journal><ArticleTitle>Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.</ArticleTitle><Pagination><MedlinePgn>289-93</MedlinePgn></Pagination><Abstract><AbstractText>Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in Wuchereria bancrofti microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tisch</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio 44106-7286, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bockarie</LastName><ForeName>Moses J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Dimber</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Kiniboro</LastName><ForeName>Benson</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tarongka</LastName><ForeName>Nandao</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hazlett</LastName><ForeName>Fred E</ForeName><Initials>FE</Initials></Author><Author ValidYN="Y"><LastName>Kastens</LastName><ForeName>Will</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Alpers</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Kazura</LastName><ForeName>James W</ForeName><Initials>JW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI065717</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI065717-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI065717</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Trop Med Hyg</MedlineTA><NlmUniqueID>0370507</NlmUniqueID><ISSNLinking>0002-9637</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000977">Antiparasitic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C045193">Wuchereria antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2007 Jan;76(1):62-6</RefSource><PMID Version="1">17255231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Biochem Parasitol. 1995 Jul;73(1-2):231-9</RefSource><PMID Version="1">8577331</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Microbiol Immunol. 2003 Feb;192(1):9-14</RefSource><PMID Version="1">12592558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Parasitol. 1993 Mar;44(1):45-8</RefSource><PMID Version="1">8516633</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2006 Jul;100(7):656-62</RefSource><PMID Version="1">16414095</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2002 Dec;96 Suppl 2:S55-9</RefSource><PMID Version="1">12625918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Parasitol. 2006;61:395-441</RefSource><PMID Version="1">16735170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2007 Feb;23(2):78-82</RefSource><PMID Version="1">17174604</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2002 Dec;96 Suppl 2:S41-6</RefSource><PMID Version="1">12625916</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1996 Sep;55(3):333-7</RefSource><PMID Version="1">8842125</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2004 Sep 3;3(1):9</RefSource><PMID Version="1">15347425</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2002 Dec;96 Suppl 2:S15-40</RefSource><PMID Version="1">12630391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Parasitol. 1990 Dec;41(4):403-6</RefSource><PMID Version="1">2075384</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Dec 5;347(23):1841-8</RefSource><PMID Version="1">12466508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Today. 1997 Oct;13(10):401-4</RefSource><PMID Version="1">15275155</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2006 Nov;22(11):529-35</RefSource><PMID Version="1">16971182</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2000 Sep;5(9):591-4</RefSource><PMID Version="1">11044272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Mar 25;367(9515):992-9</RefSource><PMID Version="1">16564361</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2001 May-Jun;95(3):277-9</RefSource><PMID Version="1">11490996</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2005 Aug;5(8):514-23</RefSource><PMID Version="1">16048720</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2001 Oct 1;184(7):898-904</RefSource><PMID Version="1">11528594</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1997 Feb;175(2):489-92</RefSource><PMID Version="1">9203681</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000977" MajorTopicYN="N">Antiparasitic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010219" MajorTopicYN="N" Type="Geographic">Papua New Guinea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS77308</OtherID><OtherID Source="NLM">PMC2590750</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18256431</ArticleId><ArticleId IdType="pii">78/2/289</ArticleId><ArticleId IdType="pmc">PMC2590750</ArticleId><ArticleId IdType="mid">NIHMS77308</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003385 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003385 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:18256431
|texte= Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18256431" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |